What was the primary finding of the correlative data presented from the CARTITUDE-4 study regarding the use of cilta-cel?
Cilta-cel had no significant impact on immune fitness in patients with R/R multiple myeloma
Cilta-cel improved immune fitness, but only in patients who received it as a later line of treatment
Earlier use of cilta-cel was correlated with better immune fitness, which may contribute to improved treatment outcomes